SKYI · Sky Century Investment, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These and other factors raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification.”View the 10-Q filed Jul 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jan 30, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jan 30, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SKYI
this stock
Sky Century Investment, Inc.
|
$866,587 | — | +47.4% | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -1.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jan 30, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SKYI | -23.3% | -42.5% | — | -8.0% | — |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -22.8% | -41.3% | — | -7.3% | — |